ZA200406147B - Method and compound for the prophylaxis or treatment of an immunodeficiency condition, such as AIDS - Google Patents
Method and compound for the prophylaxis or treatment of an immunodeficiency condition, such as AIDS Download PDFInfo
- Publication number
- ZA200406147B ZA200406147B ZA200406147A ZA200406147A ZA200406147B ZA 200406147 B ZA200406147 B ZA 200406147B ZA 200406147 A ZA200406147 A ZA 200406147A ZA 200406147 A ZA200406147 A ZA 200406147A ZA 200406147 B ZA200406147 B ZA 200406147B
- Authority
- ZA
- South Africa
- Prior art keywords
- hiv
- aids
- compound
- drug
- prophylaxis
- Prior art date
Links
- 208000030507 AIDS Diseases 0.000 title claims description 49
- 150000001875 compounds Chemical class 0.000 title claims description 36
- 238000000034 method Methods 0.000 title claims description 19
- 238000011282 treatment Methods 0.000 title claims description 18
- 206010061598 Immunodeficiency Diseases 0.000 title claims description 15
- 208000029462 Immunodeficiency disease Diseases 0.000 title claims description 15
- 230000007813 immunodeficiency Effects 0.000 title claims description 15
- 238000011321 prophylaxis Methods 0.000 title claims description 13
- 210000004027 cell Anatomy 0.000 claims description 33
- 241000700605 Viruses Species 0.000 claims description 24
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 21
- NXQMCAOPTPLPRL-UHFFFAOYSA-N 2-(2-benzoyloxyethoxy)ethyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCCOCCOC(=O)C1=CC=CC=C1 NXQMCAOPTPLPRL-UHFFFAOYSA-N 0.000 claims description 20
- 150000002334 glycols Chemical class 0.000 claims description 14
- 230000010076 replication Effects 0.000 claims description 7
- 239000012676 herbal extract Substances 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 3
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 229940079593 drug Drugs 0.000 description 44
- 239000003814 drug Substances 0.000 description 44
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 40
- 208000031886 HIV Infections Diseases 0.000 description 23
- 238000012360 testing method Methods 0.000 description 17
- 208000037357 HIV infectious disease Diseases 0.000 description 16
- 239000003443 antiviral agent Substances 0.000 description 16
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 16
- 230000000694 effects Effects 0.000 description 13
- 208000015181 infectious disease Diseases 0.000 description 13
- 239000002777 nucleoside Substances 0.000 description 11
- 150000003833 nucleoside derivatives Chemical class 0.000 description 9
- 108010016183 Human immunodeficiency virus 1 p16 protease Proteins 0.000 description 6
- 230000000840 anti-viral effect Effects 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 229930014626 natural product Natural products 0.000 description 6
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 6
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 102100034343 Integrase Human genes 0.000 description 5
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 230000000798 anti-retroviral effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 125000003831 tetrazolyl group Chemical group 0.000 description 4
- 231100001274 therapeutic index Toxicity 0.000 description 4
- 231100000041 toxicology testing Toxicity 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- QAGYKUNXZHXKMR-UHFFFAOYSA-N CPD000469186 Natural products CC1=C(O)C=CC=C1C(=O)NC(C(O)CN1C(CC2CCCCC2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-UHFFFAOYSA-N 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- -1 MKC-422 Chemical compound 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 108010047620 Phytohemagglutinins Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 238000003255 drug test Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 231100001231 less toxic Toxicity 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 229960000884 nelfinavir Drugs 0.000 description 2
- QAGYKUNXZHXKMR-HKWSIXNMSA-N nelfinavir Chemical compound CC1=C(O)C=CC=C1C(=O)N[C@H]([C@H](O)CN1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(=O)NC(C)(C)C)CSC1=CC=CC=C1 QAGYKUNXZHXKMR-HKWSIXNMSA-N 0.000 description 2
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 description 2
- 125000003835 nucleoside group Chemical group 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 230000001885 phytohemagglutinin Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- GWKIPRVERALPRD-ZDUSSCGKSA-N (s)-4-isopropoxycarbonyl-6-methoxy-3-methylthiomethyl-3,4-dihydroquinoxalin-2(1h)-thione Chemical compound N1C(=S)[C@H](CSC)N(C(=O)OC(C)C)C2=CC(OC)=CC=C21 GWKIPRVERALPRD-ZDUSSCGKSA-N 0.000 description 1
- ZNFFMCYSMBXZQU-NSHDSACASA-N 5-chloro-8-methyl-7-(3-methyl-but-2-enyl)-6,7,8,9-tetrahydro-2h-2,7,9a-triaza-benzo[cd]azulene-1-thione Chemical compound C1N(CC=C(C)C)[C@@H](C)CN2C(=S)NC3=CC=C(Cl)C1=C32 ZNFFMCYSMBXZQU-NSHDSACASA-N 0.000 description 1
- 241000251557 Ascidiacea Species 0.000 description 1
- 241001339134 Calanoides Species 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 108010010369 HIV Protease Proteins 0.000 description 1
- 229940099797 HIV integrase inhibitor Drugs 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 241001596291 Namibia Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 229960004150 aciclovir Drugs 0.000 description 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000002832 anti-viral assay Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000011225 antiretroviral therapy Methods 0.000 description 1
- 229940124522 antiretrovirals Drugs 0.000 description 1
- 239000003903 antiretrovirus agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 238000010260 bioassay-guided fractionation Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000007541 cellular toxicity Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine mesylate Natural products CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000000423 heterosexual effect Effects 0.000 description 1
- 239000003084 hiv integrase inhibitor Substances 0.000 description 1
- 230000000652 homosexual effect Effects 0.000 description 1
- 230000005571 horizontal transmission Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229930190794 lamellarin Natural products 0.000 description 1
- CJPLEFFCVDQQFZ-UHFFFAOYSA-N loviride Chemical compound CC(=O)C1=CC=C(C)C=C1NC(C(N)=O)C1=C(Cl)C=CC=C1Cl CJPLEFFCVDQQFZ-UHFFFAOYSA-N 0.000 description 1
- 229950006243 loviride Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960000689 nevirapine Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229960000311 ritonavir Drugs 0.000 description 1
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 238000009118 salvage therapy Methods 0.000 description 1
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical class CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 229950011282 tivirapine Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34405502P | 2002-01-03 | 2002-01-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200406147B true ZA200406147B (en) | 2006-06-28 |
Family
ID=27662950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200406147A ZA200406147B (en) | 2002-01-03 | 2004-08-02 | Method and compound for the prophylaxis or treatment of an immunodeficiency condition, such as AIDS |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US7144922B2 (de) |
| EP (1) | EP1469844A4 (de) |
| AU (1) | AU2003231959A1 (de) |
| WO (1) | WO2003063681A2 (de) |
| ZA (1) | ZA200406147B (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10811908B2 (en) | 2014-09-25 | 2020-10-20 | Supply, Inc. | System and method for wireless power reception |
| US11178625B2 (en) | 2017-06-06 | 2021-11-16 | Supply, Inc. | Method and system for wireless power delivery |
| EP3763015A4 (de) | 2018-03-08 | 2021-12-29 | Supply, Inc. | Verfahren und system für drahtlose stromversorgung |
| US11241410B2 (en) * | 2020-05-18 | 2022-02-08 | Amanuel Tesfazion | Method and compound for the treatment of covid-19 |
| US20230321025A1 (en) * | 2020-06-23 | 2023-10-12 | Lydia Seifu | Method and compound for the treatment and elimination of an immunodeficiency condition |
| JP2023540893A (ja) * | 2020-08-28 | 2023-09-27 | リーチ パワー，インコーポレイテッド | ワイヤレス電力供給のための方法およびシステム |
| EP4324071A1 (de) | 2021-04-14 | 2024-02-21 | Reach Power, Inc. | System und verfahren für drahtlose stromnetzwerke |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3833520A (en) * | 1973-01-05 | 1974-09-03 | Tenneco Chem | Method of controlling microbial growth in polyvinyl halide resin compositions |
| ES469531A1 (es) * | 1978-05-05 | 1978-12-01 | Alter Lab | Un procedimiento de preparacion de ciertos diesteres de eti-lenglicol. |
| US5492692A (en) * | 1993-08-17 | 1996-02-20 | University Of Kentucky Research Foundation | Coated products with potent anti-HIV and antimicrobial properties |
| US5684042A (en) * | 1997-01-10 | 1997-11-04 | Medlogic Global Corporation | Cyanoacrylate compositions comprising an antimicrobial agent |
-
2003
- 2003-01-03 AU AU2003231959A patent/AU2003231959A1/en not_active Abandoned
- 2003-01-03 WO PCT/US2003/000002 patent/WO2003063681A2/en not_active Application Discontinuation
- 2003-01-03 EP EP03734943A patent/EP1469844A4/de not_active Withdrawn
- 2003-01-03 US US10/335,737 patent/US7144922B2/en not_active Expired - Fee Related
-
2004
- 2004-08-02 ZA ZA200406147A patent/ZA200406147B/en unknown
-
2006
- 2006-12-05 US US11/633,449 patent/US20070093550A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US7144922B2 (en) | 2006-12-05 |
| EP1469844A2 (de) | 2004-10-27 |
| EP1469844A4 (de) | 2007-07-11 |
| AU2003231959A1 (en) | 2003-09-02 |
| US20030225159A1 (en) | 2003-12-04 |
| WO2003063681A3 (en) | 2003-11-20 |
| WO2003063681A2 (en) | 2003-08-07 |
| US20070093550A1 (en) | 2007-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20070093550A1 (en) | Method and compound for the prophylaxis or treatment of an immunodeficiency condition, such as AIDS | |
| US6093702A (en) | Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread | |
| Robinson Jr | L-chicoric acid, an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase, improves on the in vitro anti-HIV-1 effect of Zidovudine plus a protease inhibitor (AG1350) | |
| JPH05500824A (ja) | Ｈｉｖ関連疾病の処置での漢方薬草抽出物 | |
| JP2009512716A (ja) | Ｈｉｖ−１キャプシド構築の低分子阻害剤 | |
| US20150238511A1 (en) | Synergistic antiviral compositions comprising a viral attachment inhibitor, an integration inhibitor, and a proviral transcription inhibitor, and their use | |
| Garcia-Broncano et al. | Efficacy of carbosilane dendrimers with an antiretroviral combination against HIV-1 in the presence of semen-derived enhancer of viral infection | |
| Guss | The acquired immune deficiency syndrome: an overview for the emergency physician, Part 1 | |
| Qiu et al. | Poly (4-styrenesulfonic acid-co-maleic acid) is an entry inhibitor against both HIV-1 and HSV infections–Potential as a dual functional microbicide | |
| WO1992002530A1 (en) | Hexa-n-(o-hydroxybenzyl) neomycin b for inhibiting human retroviruses and for the treatment of aids | |
| US7897640B2 (en) | Method of treatment of virus infections using shikonin compounds | |
| Patuwo et al. | The changing role of HIV-associated oral candidiasis in the era of HAART | |
| Neupane et al. | Off label medication to combat COVID-19: review Results to Date | |
| WO1996001110A2 (en) | Anti-hiv triple combination | |
| CN112315959A (zh) | 卟啉类化合物在制备抗冠状病毒药物中的应用 | |
| Han et al. | Chinese clinical studies for pharmacological treatments of coronavirus disease 2019 (COVID-19) | |
| US20230321025A1 (en) | Method and compound for the treatment and elimination of an immunodeficiency condition | |
| CN114886901B (zh) | 白桦脂酸和rn-18在制备抗猪流行性腹泻病毒药物中的应用 | |
| Schinazi et al. | Effect of dehydroepiandrosterone in lymphocytes and macrophages infected with human immunodeficiency viruses | |
| Hassan et al. | Pharmacologic agents for the management of COVID-19: a review | |
| Kang et al. | Chinese herbal formula XQ-9302: pilot study of its clinical and in vitro activity against human immunodeficiency virus | |
| Zirafi et al. | HIV enhancing activity of semen impairs the antiviral efficacy of microbicides | |
| Wu et al. | Antiviral activity of EFdA against NRTI-sensitive and-resistant strains of HIV-2 | |
| Mabayoje | HIV/AIDS: the past, present and future | |
| Doa’a et al. | Assessment of the effectiveness of two strategies of Antiretroviral therapy in Yemen |